Brief: Akari Therapeutics' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1
24/09/2025 14:41
Sept 24 (Reuters) - Akari Therapeutics PLC AKTX.O: AKARI THERAPEUTICS’ PRECLINICAL DATA DEMONSTRATES THE POTENTIAL OF ITS NOVEL ADC SPLICEOSOME MODULATING PAYLOAD, PH1 AKARI : PLANS TO TEST AGAINST DIFFERENT PROSTATE CANCER TARGETS THE HYPOTHESIS THAT ARPI PLUS PH1 ADCS MAY SLOW DEVELOPMENT OF RESISTANCE Source text: ID:nGNX9td05g Further company coverage: AKTX.O